Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ESCORT: Camrelizumab vs Chemotherapy in Advanced ESCC
NCT03099382Phase 3Completed
- Sponsor
- Hengrui
- Start
- May 2017
- Primary completion
- May 2019
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 3 trial of camrelizumab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Hengrui. Started May 2017; status: completed.
02
Drugs
camrelizumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT03099382.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03099382.